2014
DOI: 10.1007/s12032-014-0204-4
|View full text |Cite
|
Sign up to set email alerts
|

SLC19A1 hot spot for MTX plasma concentration

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 3 publications
(2 reference statements)
0
3
0
Order By: Relevance
“…In fact, Treviño et al40 performed a genome-wide association study in patients with ALL and found rs4149081 and rs11045879 in SLCO1B1 strongly associated for the first time with MTX clearance, and this association was widely confirmed by subsequent studies 11,39,41. As a result, other works have focused their interest on the analysis of polymorphism in MTX transporters, finding several SNPs in genes such as SLC19A1 , ABCC4 , or ABCC2 also associated with MTX levels and other toxicities 4244…”
Section: Resultsmentioning
confidence: 94%
“…In fact, Treviño et al40 performed a genome-wide association study in patients with ALL and found rs4149081 and rs11045879 in SLCO1B1 strongly associated for the first time with MTX clearance, and this association was widely confirmed by subsequent studies 11,39,41. As a result, other works have focused their interest on the analysis of polymorphism in MTX transporters, finding several SNPs in genes such as SLC19A1 , ABCC4 , or ABCC2 also associated with MTX levels and other toxicities 4244…”
Section: Resultsmentioning
confidence: 94%
“…The studied polymorphism is the focused genetic background that is widely discussed for its effect on methotrexate dose in leukemia treatment. [4,7] In this study, it can be seen that the GG genotype requires the highest energy per mole which imply the least change in the formation of outcome. This is concordant with the report by Wang et al [4] Based our prediction, the amount of serum methotrexate in TT genotype is 1.10 and 1.20 times more than GT and GG, respectively.…”
Section: Discussionmentioning
confidence: 61%
“…The strongest evidence is available for the R27H mutation. Several recent studies have associated the R27H mutation with increased MTX plasma concentration and toxicity, although no RFC-1 polymorphism has been found to significantly affect MTX response in GWAS analyses [41], [42], [43]. It is known that MTX responses differ between ethnic groups, especially between Asian and Caucasian populations [44].…”
Section: Pharmacogenetic Considerations For Mtxmentioning
confidence: 99%